Piramal Pharma's FY26 sustainability report noted a ₹1.15 Cr penalty for environmental compliance and one voluntary Prazosin product recall.

The company demonstrated strong ESG performance, utilizing 40.9% renewable energy, achieving 95% waste recovery, and recycling 191,887 kL of water across global sites.